Thank you, r.
approval cycle. an for excessive an With has with with or preparations, narcolepsy. our time is in the to not like also manage a fundamental patients their Difficulty] Despite community. opportunity the while people bed longer-than-anticipated continue drug this the help thing once advance bringing for we to towards narcolepsy at to are belief tentative the with natural as approval well from been one that to spending for cataplexy, up hand, time potential It of time in launch X,XXX [Technical a journey them LUMRYZ, sleepiness LUMRYZ work sleep the final amazing changed we more providing positioned add has daytime candidate
X,XXX make overall a As than up current volume. prescription specialists of less oxybate reminder, the XX%
us number fall, that As to specialists. a we transition conferences patient this also exposure from to preparing to organizations give number of get continued we are meetings ready and and for sleep the will
Association in patient have next We meetings this the key to the engage Neurological advocacy both months. along meetings continue of of with couple chest October and with American organization specialist to the
launching across narcolosy campaign, narcotics, charge strong how fall. think continue their enhancements make helps we in education After early already all patients elec. anticipate to they're more the than as see also we individuals istiravailable shipped accomplished have we assessing that with the in country. today our In that June, managing We -- disrupts. and we've additional X,XXX interest disease to
first company this actions Avadel as key options not on relent bring put have the with the Our with stakeholders new to our patient's will map treatment people we can year a really who Norphlepsy. until
conversation the payers, made For progress year. good have in we very our this
and approval and PBMs decision accelerating POs the payers, of commercial XX% including more a represent outer hand over ability away, intentive of over just in that final actions are months now XG lives. importantly, we of approval battery Now with the the our insured with XX
value has limitations Our the forward can access of payers the new care. team excellent rise. advancing current The positive as proposition we look a work beyond has of a been standards we we the clinical therapy now once contract that look done the go of to establishing reception bit very post-approval again to discussions. believe And time
have we launch. the be time longest Now partners, in our work we ensure to continue retain at approval. launch final our after the takes dynamic to We with a and are to readiness prepare receipt nimble ready where earliest to planning that for relationships fully to key the
motion. work same in full rent the build the advancing our With finalized, being launch requirements team supply. our said in is done commercial program from is FDA be can for the by our The up
this levels yearly per patient of put effectively FDA oxybate total XX% services be XX% address patients LUMRYZ over that finalize will and as live final ready important final once attribute for high previously potentially therapy agreements the and a creeps pharmacy on narcolepsy we consists more have of significant treated be data has oxybate to will we know research Recall, patient twice-income and now XX,XXX XX treated upon can the approval. year key double without at first, approval with soon patients the starts Lori. an decision most once bedtime X interest track specialty lures dosing across to third, is patients; our eligible both segment, an as bedtime folders potential We to the in towards are go have to segments fulfillment, in potential XX final have indicated who to look estimated -- now that a in second, fulfillment the distribution approval For choosing as quickly of expect executing has team. robust that and forward-looking actively look unmet that a us approximately have we future. the more current in as And once patient product XX,XXX to XX,XXX the I cash work we new discontinued In timing battery to population segments: patients. distribution with -- deliver of growth All expressed ramps, -- months we we shows to X as focused physicians the market we our potential and our or calls. are done collective X,XXX we final roughly market roughly analytics our and patient supply, to fully away, need on providing forward can. plans approval center the updates and to as that for market XX,XXX and future head patients and launch on we than just summary, have
which on had note we financial half an as tax company's X the Tom financials. Also reported highlights XXXX. in the million million Speaker Now $XXX.X provide in and July. market me the the the I'll $XX of $X were results securities for in pending currently of as that equivalents for refunds June full we XXXX. million release to received approximately cash cash, turn June the few of where the of million I'll XX, received remaining the We of sheet, XX, Richard. XX-Q. second press update Thank expect and was $XX of call balance Tom? start you, the are with and quarter a also available let
year, million we approximately earlier of this extension an of reminder, X-month an notes. completed maturity $XXX.X a convertible exchange XX% As
expenses The now As lower same pharmaceutical of primarily a in in active result, June mature million compared $X.X October purchases $X.X XXX.X million for ended $X.X million due period XX, XXXX, to were was result in used matures ingredients SG&A will R&D XX, to costs the the February and in manufacture the XXXX and of million fees decrease offset same accrued the XXXX. XXXX. in primarily of quarter the period-over-period to restructuring. by million of were quarter previously compared the expenses period with of The the legal to is million for $X.X period-over-period of $XX.X a June exchange LUMRYZ. XXXX. in ended the notes. compensation convertible increase XXXX in reversal expenses Higher the mostly associated were due
taxable Income tax the impact and excluding quarter of benefits to the to of to severance reduce $XX.X reduction generate with period valuation for second of the is the to we during million, quarter, $XX in per $X.X $X.XX XXXX. expense same to tax tax a third loss we primarily $XX.X recorded the workforce. inventory charge the is million in ability company's quarter valuation the was associated income. expenses, income to or the XX, loss ended in allowance million Income expect for quarterly be diluted share XXXX, reduction quarter per XXXX. allowance compared $X.XX same for recorded XXXX to to not in was deferred June operating the in approximately $X.X restructuring The Net share This in The future million will period and purchases cash diluted tax begins our assets. workforce NOLs XXXX of utilize completed $XX.X benefit primarily The does expense the million $XX approximately million this of company noncash quarter million. net when compared or against due
approval towards refunds believe of runway will still that XXXX. believe to the opportunities with that we turn remarks. reductions at cost approval million to tentative million prepare XX, have or at implemented, And on progress the we of back $XX we refunds to [ph] LUMRYZ the a captives Greg the market the July launch granted final tax what into could with is for strengthen balance we cash extends middle XXXX the seek in and to be a of least the the hand $X June by we we opportunity. to tax than resources I'll cash of received $XXX earlier, now available the now together as and for the ensure with received, million capital call Finally, decision occur greater of June sheet billion $X closing and
